Underutilization of Treatment for Black Adults With Apparent Treatment-Resistant Hypertension
- 14 September 2020
- journal article
- research article
- Published by Wolters Kluwer Health in Hypertension
- Vol. 76 (5) , 1600-1607
Abstract
Resistant hypertension, defined as blood pressure levels above goal while taking ≥3 classes of antihypertensive medication or ≥4 classes regardless of blood pressure level, is associated with increased cardiovascular disease risk. The 2018 American Heart Association Scientific Statement on Resistant Hypertension recommends healthy lifestyle habits and thiazide-like diuretics and mineralocorticoid receptor antagonists for adults with resistant hypertension. The term apparent treatment-resistant hypertension (aTRH) is used when pseudoresistance cannot be excluded. We estimated the use of healthy lifestyle factors and recommended antihypertensive medication classes among US Black adults with aTRH. Data were pooled for Black participants in the JHS (Jackson Heart Study) in 2009 to 2013 (n=2496) and the REGARDS study (Reasons for Geographic and Racial Differences in Stroke) in 2013 to 2016 (n=3786). Outcomes included lifestyle factors (not smoking, not consuming alcohol, ≥75 minutes of vigorous-intensity or ≥150 minutes of moderate or vigorous physical activity per week, and body mass index 2 ) and recommended antihypertensive medications (thiazide-like diuretics and mineralocorticoid receptor antagonists). Overall, 28.3% of participants who reported taking antihypertensive medication had aTRH. Among participants with aTRH, 14.5% and 1.2% had ideal levels of 3 and 4 of the lifestyle factors, respectively. Also, 5.9% of participants with aTRH reported taking a thiazide-like diuretic, and 9.8% reported taking a mineralocorticoid receptor antagonist. In conclusion, evidence-based lifestyle factors and recommended pharmacological treatment are underutilized in Black adults with aTRH. Increased use of lifestyle recommendations and antihypertensive medication classes specifically recommended for aTRH may improve blood pressure control and reduce cardiovascular disease–related morbidity and mortality among US Black adults. Graphic A graphic abstract is available for this article.Keywords
This publication has 35 references indexed in Scilit:
- Apparent and true resistant hypertension: definition, prevalence and outcomesJournal of Human Hypertension, 2014
- Life’s Simple 7 and Risk of Incident StrokeStroke, 2013
- Chlorthalidone Compared With Hydrochlorothiazide in Reducing Cardiovascular EventsHypertension, 2012
- Aldosterone Blockers (Mineralocorticoid Receptor Antagonism) and Potassium-Sparing DiureticsThe Journal of Clinical Hypertension, 2011
- Chlorthalidone Reduces Cardiovascular Events Compared With HydrochlorothiazideHypertension, 2011
- Defining and Setting National Goals for Cardiovascular Health Promotion and Disease ReductionCirculation, 2010
- Resistant Hypertension: Diagnosis, Evaluation, and TreatmentCirculation, 2008
- The Reasons for Geographic and Racial Differences in Stroke Study: Objectives and DesignNeuroepidemiology, 2005
- Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)JAMA, 2002
- PATHOPHYSIOLOGY AND TREATMENT IMPLICATIONS OF HYPERTENSION IN THE AFRICAN-AMERICAN POPULATIONEndocrinology and Metabolism Clinics of North America, 1997